ClinicalTrials.gg
CompletedNCT03844074Updated Mar 19, 2025

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

A Phase 3 interventional study of bevacizumab and ranibizumab in Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration and Wet Macular Degeneration, sponsored by Outlook Therapeutics, Inc.. Completed at 9 sites in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.

Primary conditionWet Macular DegenerationRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Wet Macular Degeneration
Why
  1. The study's listed conditions name Wet Macular Degeneration, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Outlook Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2021.
  • Registered 4 months after the study started (first participant enrolled Oct 2018, registered Feb 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

02

Conditions studied

  • Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Wet Macular Degeneration

Browse trials for

Keywords

  • Subfoveal Choroidal Neovascularization
03

In context

Wet Macular Degeneration Reclassified

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

This study's enrollment of 61 is below the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.

Browse Wet Macular Degeneration studies →

Lead sponsor

Outlook Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Compared within Wet Macular Degeneration, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active primary or recurrent Subfoveal Choroidal Neovascularization lesions secondary to Age-related macular degeneration (AMD) in the study eye
  • Best corrected visual acuity of 20/40 to 20/320
  • Study eye must:

    • Have active leakage on Fluorescein Angiogram involving the fovea
    • Have edema involving the fovea
    • Be free of foveal scarring
    • Be free of foveal atrophy

Exclusion criteria

Exclusion Criteria:

  • Previous use of anti-VEGF or bevacizumab within 6 weeks
  • Previous subfoveal focal laser photocoagulation in the study eye
  • Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization
  • Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss within 1 year
  • Active intraocular inflammation (grade trace or above) in the study eye
  • Current vitreous haemorrhage in the study eye
  • Polypoidal choroidal vasculopathy (PCV) confirmed by indocyanine green angiography (ICGA)
  • History of idiopathic or -associated uveitis in either eye
  • Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
  • Premenopausal women not using adequate
  • Current treatment for active systemic infection
  • Known allergy to any component of the study drug or history of allergy to fluorescein or indocyanine green, not amenable to treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    bevacizumab

    ONS-5010

    Biological: bevacizumab

  • Active comparator
    ranibizumab

    Biological: ranibizumab

Interventions

  • Biologicalbevacizumab

    1.25 mg, intravitreal injection

    Also known as: ONS-5010

  • Biologicalranibizumab

    0.5mg, intravitreal injection

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score

    BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.

    Time frame: Baseline, 11 months

Secondary outcomes

  1. Mean change in the best corrected visual acuity over time

    BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.

    Time frame: Baseline, monthly to 11 months

  2. Proportion of participants who gain at least 10 letters in the best corrected visual acuity score

    BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.

    Time frame: Baseline, 11 months

  3. Proportion of participants who gain at least 5 letters in the best corrected visual acuity score

    BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.

    Time frame: Baseline, 11 months

  4. Proportion of participants who lose fewer than 15 letters in the best corrected visual acuity score

    BCVA to be assessed as letters read using the ETDRS charts. A negative change represents a decrease in visual acuity.

    Time frame: Baseline, 11 months

  5. Proportion of participants with visual-acuity Snellen equivalent of 20/200 or worse

    Time frame: Baseline, 11 months

  6. Percentage of participants with ocular adverse events, non-ocular adverse events, grade 3 and above laboratory abnormalities, and vital sign abnormalities

    Time frame: 11 months, 12 months

07

Study locations

9 sites
  • Clinical Site
    Hurstville, New South Wales, Australia
  • Clinical Site
    Liverpool, New South Wales, Australia
  • Clinical Site
    Sydney, New South Wales, Australia
  • Clinical Site
    Westmead, New South Wales, Australia
  • Clinical Site
    Brisbane, Queensland, Australia
  • Clinical Site
    Adelaide, South Australia, Australia
  • Clinical Site
    Hobart, Tasmania, Australia
  • Clinical Site
    Essendon, Victoria, Australia
  • Clinical Site
    Glen Waverley, Victoria, Australia
08

References and documents

Individual participant data

Plan to share: Undecided — Data will not be shared until all global regulatory filings are complete.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jul 2020, 21 months.

Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2019
First posted
Feb 18, 2019
StartActual
Oct 1, 2018
Primary completionActual
Jul 23, 2020
CompletionActual
Aug 13, 2020
Results delay requested
May 4, 2021
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03844074
Lead sponsor
Outlook Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 18, 2019
Start date
Oct 1, 2018
Primary completion
Jul 23, 2020
Completion
Aug 13, 2020
Last update
Mar 19, 2025

Study contacts

Jennifer M Kissner, PhD
study director · Outlook Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion